Granting marketing authorisation for medicines in South East European countries: The point of view of the authority
Authors:
- 31 August 2010
- journal article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 57 (2-3) , 325-332
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines AgencyEuropean Journal of Clinical Pharmacology, 2009
- Centralized National Ethical Review of Clinical Trials in CroatiaCroatian Medical Journal, 2009
- Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung CancerBiomolecules and Biomedicine, 2008
- Registrierung neuer Arzneimittel in EuropaOnkologie, 2008
- Issues with regulatory pharmacovigilance in East European countries: The industry perspectiveToxicology Letters, 2007
- Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s DiseaseOncology Research and Treatment, 2005
- Off label and unlicensed drugs use in paediatric cardiologyEuropean Journal of Clinical Pharmacology, 2005
- Overview of the European Regulatory Approval SystemJournal of Ambulatory Care Management, 2004
- The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcomeEuropean Journal of Clinical Pharmacology, 2002